Global HER2 Targeted Therapy Market
Global HER2 Targeted Therapy Market

HER2 Targeted Therapy Comprehensive Study by Therapy (Immunotherapy, Neoadjuvant Therapy), End Users (Hospitals, Clinics), Treatment (Herceptin, Perjeta, Neratinib, Trastuzumab, Others), Distribution Channel (Online {Company Website, E-Commerce Website}, Offline {Medical Stores, Supermarkets, Distributors, Suppliers}) Players and Region - Global Market Outlook to 2026

HER2 Targeted Therapy Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Sep 2021 Edition 213 Pages 218 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Industry Background:
HER2 treatments are a class of drugs that are used to treat HER2-positive breast cancer at all stages, from early-stage to metastatic. Breast cancer that has spread to other regions of the body, such as the bones or liver, is known as metastatic breast cancer. The HER2 gene malfunctions in HER2-positive breast cancer and produces too many copies of itself. These additional HER2 genes result in an excess of HER2 receptor proteins. The HER2 receptors on the surface of breast cells are similar to ears or antennae. Signals are received by the HER2 receptors, which drive the cell to grow and reproduce.This growth is primarily driven by Breast Cancer Cases are Increasing is and there is a Great Demand for Effective Therapeutics.

Globally, a noticeable market trend is evident Introduction of New ADC Kadcyla is Being Widely used in HER2+ Breast Cancer. Major Players, such as Roche (Switzerland), Sanofi (France), Byondis (Netherlands), Novartis (Switzerland), Astrazeneca (United Kingdom), Daiichi Sankyo (Japan), Genentech (United States), Bristol Myers Squibb (United States), Eisai (Japan) and Kyowa Kirin (Japan) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

In March 2019 AstraZeneca released a statement stating the Collaboration With Daiichi Sankyo. The partnership is in line with AstraZeneca's science-driven oncology strategy, which is built around four main scientific platforms: tumour drivers and resistance, DNA damage response, Immuno-Oncology, and ADCs. An initial regulatory filing for patients with advanced or resistant breast cancer is expected in the second part of 2019. More research is being done for the treatment of breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, and colorectal cancer. Except in Japan, where Daiichi Sankyo will retain exclusive rights, the businesses will jointly develop and commercialize trastuzumab deruxtecan.

Market Drivers
  • Breast Cancer Cases are Increasing is and there is a Great Demand for Effective Therapeutics

Market Trend
  • Introduction of New ADC Kadcyla is Being Widely used in HER2+ Breast Cancer

Restraints
  • Patients Resistance to Therapy Both Primary or Acquired, is Still a Challenging Issue

Opportunities
The Patient Population with Brain Metastases is the Most Untapped Market
Challenges
Side-Effects of the Drugs and the Therapy and The Therapy is Very Expensive and it Takes a Lot of Time for Completion

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, HER2 Targeted Therapy Study Sheds Light on
— The HER2 Targeted Therapy Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the HER2 Targeted Therapy industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where HER2 Targeted Therapy industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Frequently Asked Questions (FAQ):

1. What are the years considered in the HER2 Targeted Therapy Market?
Historical year: 2016-2020; Base year: 2020; Forecast period: 2021 to 2026

2. Who are the key players profiled in the HER2 Targeted Therapy Market?
Companies that are profiled in Global HER2 Targeted Therapy Market are Roche (Switzerland), Sanofi (France), Byondis (Netherlands), Novartis (Switzerland), Astrazeneca (United Kingdom), Daiichi Sankyo (Japan), Genentech (United States), Bristol Myers Squibb (United States), Eisai (Japan) and Kyowa Kirin (Japan) etc.

3. What is HER2 Targeted Therapy Market?
HER2 treatments are a class of drugs that are used to treat HER2-positive breast cancer at all stages, from early-stage to metastatic. Breast cancer that has spread to other regions of the body, such as the bones or liver, is known as metastatic breast cancer. The HER2 gene malfunctions in HER2-positive breast cancer and produces too many copies of itself. These additional HER2 genes result in an excess of HER2 receptor proteins. The HER2 receptors on the surface of breast cells are similar to ears or antennae. Signals are received by the HER2 receptors, which drive the cell to grow and reproduce.
Report Objectives / Segmentation Covered
By Therapy
  • Immunotherapy
  • Neoadjuvant Therapy

By End Users
  • Hospitals
  • Clinics

By Treatment
  • Herceptin
  • Perjeta
  • Neratinib
  • Trastuzumab
  • Others

By Distribution Channel
  • Online {Company Website, E-Commerce Website}
  • Offline {Medical Stores, Supermarkets, Distributors, Suppliers}

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Breast Cancer Cases are Increasing is and there is a Great Demand for Effective Therapeutics
    • 3.3. Market Challenges
      • 3.3.1. Side-Effects of the Drugs and the Therapy
      • 3.3.2. The Therapy is Very Expensive and it Takes a Lot of Time for Completion
    • 3.4. Market Trends
      • 3.4.1. Introduction of New ADC Kadcyla is Being Widely used in HER2+ Breast Cancer
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global HER2 Targeted Therapy, by Therapy, End Users, Treatment, Distribution Channel and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global HER2 Targeted Therapy (Value)
      • 5.2.1. Global HER2 Targeted Therapy by: Therapy (Value)
        • 5.2.1.1. Immunotherapy
        • 5.2.1.2. Neoadjuvant Therapy
      • 5.2.2. Global HER2 Targeted Therapy by: End Users (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
      • 5.2.3. Global HER2 Targeted Therapy by: Treatment (Value)
        • 5.2.3.1. Herceptin
        • 5.2.3.2. Perjeta
        • 5.2.3.3. Neratinib
        • 5.2.3.4. Trastuzumab
        • 5.2.3.5. Others
      • 5.2.4. Global HER2 Targeted Therapy by: Distribution Channel (Value)
        • 5.2.4.1. Online {Company Website, E-Commerce Website}
        • 5.2.4.2. Offline {Medical Stores, Supermarkets, Distributors, Suppliers}
      • 5.2.5. Global HER2 Targeted Therapy Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global HER2 Targeted Therapy (Price)
  • 6. HER2 Targeted Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Roche (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sanofi (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Byondis (Netherlands)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novartis (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Astrazeneca (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Daiichi Sankyo (Japan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Genentech (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bristol Myers Squibb (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Eisai (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Kyowa Kirin (Japan)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global HER2 Targeted Therapy Sale, by Therapy, End Users, Treatment, Distribution Channel and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global HER2 Targeted Therapy (Value)
      • 7.2.1. Global HER2 Targeted Therapy by: Therapy (Value)
        • 7.2.1.1. Immunotherapy
        • 7.2.1.2. Neoadjuvant Therapy
      • 7.2.2. Global HER2 Targeted Therapy by: End Users (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
      • 7.2.3. Global HER2 Targeted Therapy by: Treatment (Value)
        • 7.2.3.1. Herceptin
        • 7.2.3.2. Perjeta
        • 7.2.3.3. Neratinib
        • 7.2.3.4. Trastuzumab
        • 7.2.3.5. Others
      • 7.2.4. Global HER2 Targeted Therapy by: Distribution Channel (Value)
        • 7.2.4.1. Online {Company Website, E-Commerce Website}
        • 7.2.4.2. Offline {Medical Stores, Supermarkets, Distributors, Suppliers}
      • 7.2.5. Global HER2 Targeted Therapy Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global HER2 Targeted Therapy (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. HER2 Targeted Therapy: by Therapy(USD Million)
  • Table 2. HER2 Targeted Therapy Immunotherapy , by Region USD Million (2015-2020)
  • Table 3. HER2 Targeted Therapy Neoadjuvant Therapy , by Region USD Million (2015-2020)
  • Table 4. HER2 Targeted Therapy: by End Users(USD Million)
  • Table 5. HER2 Targeted Therapy Hospitals , by Region USD Million (2015-2020)
  • Table 6. HER2 Targeted Therapy Clinics , by Region USD Million (2015-2020)
  • Table 7. HER2 Targeted Therapy: by Treatment(USD Million)
  • Table 8. HER2 Targeted Therapy Herceptin , by Region USD Million (2015-2020)
  • Table 9. HER2 Targeted Therapy Perjeta , by Region USD Million (2015-2020)
  • Table 10. HER2 Targeted Therapy Neratinib , by Region USD Million (2015-2020)
  • Table 11. HER2 Targeted Therapy Trastuzumab , by Region USD Million (2015-2020)
  • Table 12. HER2 Targeted Therapy Others , by Region USD Million (2015-2020)
  • Table 13. HER2 Targeted Therapy: by Distribution Channel(USD Million)
  • Table 14. HER2 Targeted Therapy Online {Company Website, E-Commerce Website} , by Region USD Million (2015-2020)
  • Table 15. HER2 Targeted Therapy Offline {Medical Stores, Supermarkets, Distributors, Suppliers} , by Region USD Million (2015-2020)
  • Table 16. South America HER2 Targeted Therapy, by Country USD Million (2015-2020)
  • Table 17. South America HER2 Targeted Therapy, by Therapy USD Million (2015-2020)
  • Table 18. South America HER2 Targeted Therapy, by End Users USD Million (2015-2020)
  • Table 19. South America HER2 Targeted Therapy, by Treatment USD Million (2015-2020)
  • Table 20. South America HER2 Targeted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 21. Brazil HER2 Targeted Therapy, by Therapy USD Million (2015-2020)
  • Table 22. Brazil HER2 Targeted Therapy, by End Users USD Million (2015-2020)
  • Table 23. Brazil HER2 Targeted Therapy, by Treatment USD Million (2015-2020)
  • Table 24. Brazil HER2 Targeted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 25. Argentina HER2 Targeted Therapy, by Therapy USD Million (2015-2020)
  • Table 26. Argentina HER2 Targeted Therapy, by End Users USD Million (2015-2020)
  • Table 27. Argentina HER2 Targeted Therapy, by Treatment USD Million (2015-2020)
  • Table 28. Argentina HER2 Targeted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 29. Rest of South America HER2 Targeted Therapy, by Therapy USD Million (2015-2020)
  • Table 30. Rest of South America HER2 Targeted Therapy, by End Users USD Million (2015-2020)
  • Table 31. Rest of South America HER2 Targeted Therapy, by Treatment USD Million (2015-2020)
  • Table 32. Rest of South America HER2 Targeted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 33. Asia Pacific HER2 Targeted Therapy, by Country USD Million (2015-2020)
  • Table 34. Asia Pacific HER2 Targeted Therapy, by Therapy USD Million (2015-2020)
  • Table 35. Asia Pacific HER2 Targeted Therapy, by End Users USD Million (2015-2020)
  • Table 36. Asia Pacific HER2 Targeted Therapy, by Treatment USD Million (2015-2020)
  • Table 37. Asia Pacific HER2 Targeted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 38. China HER2 Targeted Therapy, by Therapy USD Million (2015-2020)
  • Table 39. China HER2 Targeted Therapy, by End Users USD Million (2015-2020)
  • Table 40. China HER2 Targeted Therapy, by Treatment USD Million (2015-2020)
  • Table 41. China HER2 Targeted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 42. Japan HER2 Targeted Therapy, by Therapy USD Million (2015-2020)
  • Table 43. Japan HER2 Targeted Therapy, by End Users USD Million (2015-2020)
  • Table 44. Japan HER2 Targeted Therapy, by Treatment USD Million (2015-2020)
  • Table 45. Japan HER2 Targeted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 46. India HER2 Targeted Therapy, by Therapy USD Million (2015-2020)
  • Table 47. India HER2 Targeted Therapy, by End Users USD Million (2015-2020)
  • Table 48. India HER2 Targeted Therapy, by Treatment USD Million (2015-2020)
  • Table 49. India HER2 Targeted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 50. South Korea HER2 Targeted Therapy, by Therapy USD Million (2015-2020)
  • Table 51. South Korea HER2 Targeted Therapy, by End Users USD Million (2015-2020)
  • Table 52. South Korea HER2 Targeted Therapy, by Treatment USD Million (2015-2020)
  • Table 53. South Korea HER2 Targeted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 54. Taiwan HER2 Targeted Therapy, by Therapy USD Million (2015-2020)
  • Table 55. Taiwan HER2 Targeted Therapy, by End Users USD Million (2015-2020)
  • Table 56. Taiwan HER2 Targeted Therapy, by Treatment USD Million (2015-2020)
  • Table 57. Taiwan HER2 Targeted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 58. Australia HER2 Targeted Therapy, by Therapy USD Million (2015-2020)
  • Table 59. Australia HER2 Targeted Therapy, by End Users USD Million (2015-2020)
  • Table 60. Australia HER2 Targeted Therapy, by Treatment USD Million (2015-2020)
  • Table 61. Australia HER2 Targeted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 62. Rest of Asia-Pacific HER2 Targeted Therapy, by Therapy USD Million (2015-2020)
  • Table 63. Rest of Asia-Pacific HER2 Targeted Therapy, by End Users USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific HER2 Targeted Therapy, by Treatment USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific HER2 Targeted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 66. Europe HER2 Targeted Therapy, by Country USD Million (2015-2020)
  • Table 67. Europe HER2 Targeted Therapy, by Therapy USD Million (2015-2020)
  • Table 68. Europe HER2 Targeted Therapy, by End Users USD Million (2015-2020)
  • Table 69. Europe HER2 Targeted Therapy, by Treatment USD Million (2015-2020)
  • Table 70. Europe HER2 Targeted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 71. Germany HER2 Targeted Therapy, by Therapy USD Million (2015-2020)
  • Table 72. Germany HER2 Targeted Therapy, by End Users USD Million (2015-2020)
  • Table 73. Germany HER2 Targeted Therapy, by Treatment USD Million (2015-2020)
  • Table 74. Germany HER2 Targeted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 75. France HER2 Targeted Therapy, by Therapy USD Million (2015-2020)
  • Table 76. France HER2 Targeted Therapy, by End Users USD Million (2015-2020)
  • Table 77. France HER2 Targeted Therapy, by Treatment USD Million (2015-2020)
  • Table 78. France HER2 Targeted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 79. Italy HER2 Targeted Therapy, by Therapy USD Million (2015-2020)
  • Table 80. Italy HER2 Targeted Therapy, by End Users USD Million (2015-2020)
  • Table 81. Italy HER2 Targeted Therapy, by Treatment USD Million (2015-2020)
  • Table 82. Italy HER2 Targeted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 83. United Kingdom HER2 Targeted Therapy, by Therapy USD Million (2015-2020)
  • Table 84. United Kingdom HER2 Targeted Therapy, by End Users USD Million (2015-2020)
  • Table 85. United Kingdom HER2 Targeted Therapy, by Treatment USD Million (2015-2020)
  • Table 86. United Kingdom HER2 Targeted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 87. Netherlands HER2 Targeted Therapy, by Therapy USD Million (2015-2020)
  • Table 88. Netherlands HER2 Targeted Therapy, by End Users USD Million (2015-2020)
  • Table 89. Netherlands HER2 Targeted Therapy, by Treatment USD Million (2015-2020)
  • Table 90. Netherlands HER2 Targeted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 91. Rest of Europe HER2 Targeted Therapy, by Therapy USD Million (2015-2020)
  • Table 92. Rest of Europe HER2 Targeted Therapy, by End Users USD Million (2015-2020)
  • Table 93. Rest of Europe HER2 Targeted Therapy, by Treatment USD Million (2015-2020)
  • Table 94. Rest of Europe HER2 Targeted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 95. MEA HER2 Targeted Therapy, by Country USD Million (2015-2020)
  • Table 96. MEA HER2 Targeted Therapy, by Therapy USD Million (2015-2020)
  • Table 97. MEA HER2 Targeted Therapy, by End Users USD Million (2015-2020)
  • Table 98. MEA HER2 Targeted Therapy, by Treatment USD Million (2015-2020)
  • Table 99. MEA HER2 Targeted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 100. Middle East HER2 Targeted Therapy, by Therapy USD Million (2015-2020)
  • Table 101. Middle East HER2 Targeted Therapy, by End Users USD Million (2015-2020)
  • Table 102. Middle East HER2 Targeted Therapy, by Treatment USD Million (2015-2020)
  • Table 103. Middle East HER2 Targeted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 104. Africa HER2 Targeted Therapy, by Therapy USD Million (2015-2020)
  • Table 105. Africa HER2 Targeted Therapy, by End Users USD Million (2015-2020)
  • Table 106. Africa HER2 Targeted Therapy, by Treatment USD Million (2015-2020)
  • Table 107. Africa HER2 Targeted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 108. North America HER2 Targeted Therapy, by Country USD Million (2015-2020)
  • Table 109. North America HER2 Targeted Therapy, by Therapy USD Million (2015-2020)
  • Table 110. North America HER2 Targeted Therapy, by End Users USD Million (2015-2020)
  • Table 111. North America HER2 Targeted Therapy, by Treatment USD Million (2015-2020)
  • Table 112. North America HER2 Targeted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 113. United States HER2 Targeted Therapy, by Therapy USD Million (2015-2020)
  • Table 114. United States HER2 Targeted Therapy, by End Users USD Million (2015-2020)
  • Table 115. United States HER2 Targeted Therapy, by Treatment USD Million (2015-2020)
  • Table 116. United States HER2 Targeted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 117. Canada HER2 Targeted Therapy, by Therapy USD Million (2015-2020)
  • Table 118. Canada HER2 Targeted Therapy, by End Users USD Million (2015-2020)
  • Table 119. Canada HER2 Targeted Therapy, by Treatment USD Million (2015-2020)
  • Table 120. Canada HER2 Targeted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 121. Mexico HER2 Targeted Therapy, by Therapy USD Million (2015-2020)
  • Table 122. Mexico HER2 Targeted Therapy, by End Users USD Million (2015-2020)
  • Table 123. Mexico HER2 Targeted Therapy, by Treatment USD Million (2015-2020)
  • Table 124. Mexico HER2 Targeted Therapy, by Distribution Channel USD Million (2015-2020)
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. HER2 Targeted Therapy: by Therapy(USD Million)
  • Table 136. HER2 Targeted Therapy Immunotherapy , by Region USD Million (2021-2026)
  • Table 137. HER2 Targeted Therapy Neoadjuvant Therapy , by Region USD Million (2021-2026)
  • Table 138. HER2 Targeted Therapy: by End Users(USD Million)
  • Table 139. HER2 Targeted Therapy Hospitals , by Region USD Million (2021-2026)
  • Table 140. HER2 Targeted Therapy Clinics , by Region USD Million (2021-2026)
  • Table 141. HER2 Targeted Therapy: by Treatment(USD Million)
  • Table 142. HER2 Targeted Therapy Herceptin , by Region USD Million (2021-2026)
  • Table 143. HER2 Targeted Therapy Perjeta , by Region USD Million (2021-2026)
  • Table 144. HER2 Targeted Therapy Neratinib , by Region USD Million (2021-2026)
  • Table 145. HER2 Targeted Therapy Trastuzumab , by Region USD Million (2021-2026)
  • Table 146. HER2 Targeted Therapy Others , by Region USD Million (2021-2026)
  • Table 147. HER2 Targeted Therapy: by Distribution Channel(USD Million)
  • Table 148. HER2 Targeted Therapy Online {Company Website, E-Commerce Website} , by Region USD Million (2021-2026)
  • Table 149. HER2 Targeted Therapy Offline {Medical Stores, Supermarkets, Distributors, Suppliers} , by Region USD Million (2021-2026)
  • Table 150. South America HER2 Targeted Therapy, by Country USD Million (2021-2026)
  • Table 151. South America HER2 Targeted Therapy, by Therapy USD Million (2021-2026)
  • Table 152. South America HER2 Targeted Therapy, by End Users USD Million (2021-2026)
  • Table 153. South America HER2 Targeted Therapy, by Treatment USD Million (2021-2026)
  • Table 154. South America HER2 Targeted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 155. Brazil HER2 Targeted Therapy, by Therapy USD Million (2021-2026)
  • Table 156. Brazil HER2 Targeted Therapy, by End Users USD Million (2021-2026)
  • Table 157. Brazil HER2 Targeted Therapy, by Treatment USD Million (2021-2026)
  • Table 158. Brazil HER2 Targeted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 159. Argentina HER2 Targeted Therapy, by Therapy USD Million (2021-2026)
  • Table 160. Argentina HER2 Targeted Therapy, by End Users USD Million (2021-2026)
  • Table 161. Argentina HER2 Targeted Therapy, by Treatment USD Million (2021-2026)
  • Table 162. Argentina HER2 Targeted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 163. Rest of South America HER2 Targeted Therapy, by Therapy USD Million (2021-2026)
  • Table 164. Rest of South America HER2 Targeted Therapy, by End Users USD Million (2021-2026)
  • Table 165. Rest of South America HER2 Targeted Therapy, by Treatment USD Million (2021-2026)
  • Table 166. Rest of South America HER2 Targeted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 167. Asia Pacific HER2 Targeted Therapy, by Country USD Million (2021-2026)
  • Table 168. Asia Pacific HER2 Targeted Therapy, by Therapy USD Million (2021-2026)
  • Table 169. Asia Pacific HER2 Targeted Therapy, by End Users USD Million (2021-2026)
  • Table 170. Asia Pacific HER2 Targeted Therapy, by Treatment USD Million (2021-2026)
  • Table 171. Asia Pacific HER2 Targeted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 172. China HER2 Targeted Therapy, by Therapy USD Million (2021-2026)
  • Table 173. China HER2 Targeted Therapy, by End Users USD Million (2021-2026)
  • Table 174. China HER2 Targeted Therapy, by Treatment USD Million (2021-2026)
  • Table 175. China HER2 Targeted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 176. Japan HER2 Targeted Therapy, by Therapy USD Million (2021-2026)
  • Table 177. Japan HER2 Targeted Therapy, by End Users USD Million (2021-2026)
  • Table 178. Japan HER2 Targeted Therapy, by Treatment USD Million (2021-2026)
  • Table 179. Japan HER2 Targeted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 180. India HER2 Targeted Therapy, by Therapy USD Million (2021-2026)
  • Table 181. India HER2 Targeted Therapy, by End Users USD Million (2021-2026)
  • Table 182. India HER2 Targeted Therapy, by Treatment USD Million (2021-2026)
  • Table 183. India HER2 Targeted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 184. South Korea HER2 Targeted Therapy, by Therapy USD Million (2021-2026)
  • Table 185. South Korea HER2 Targeted Therapy, by End Users USD Million (2021-2026)
  • Table 186. South Korea HER2 Targeted Therapy, by Treatment USD Million (2021-2026)
  • Table 187. South Korea HER2 Targeted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 188. Taiwan HER2 Targeted Therapy, by Therapy USD Million (2021-2026)
  • Table 189. Taiwan HER2 Targeted Therapy, by End Users USD Million (2021-2026)
  • Table 190. Taiwan HER2 Targeted Therapy, by Treatment USD Million (2021-2026)
  • Table 191. Taiwan HER2 Targeted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 192. Australia HER2 Targeted Therapy, by Therapy USD Million (2021-2026)
  • Table 193. Australia HER2 Targeted Therapy, by End Users USD Million (2021-2026)
  • Table 194. Australia HER2 Targeted Therapy, by Treatment USD Million (2021-2026)
  • Table 195. Australia HER2 Targeted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 196. Rest of Asia-Pacific HER2 Targeted Therapy, by Therapy USD Million (2021-2026)
  • Table 197. Rest of Asia-Pacific HER2 Targeted Therapy, by End Users USD Million (2021-2026)
  • Table 198. Rest of Asia-Pacific HER2 Targeted Therapy, by Treatment USD Million (2021-2026)
  • Table 199. Rest of Asia-Pacific HER2 Targeted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 200. Europe HER2 Targeted Therapy, by Country USD Million (2021-2026)
  • Table 201. Europe HER2 Targeted Therapy, by Therapy USD Million (2021-2026)
  • Table 202. Europe HER2 Targeted Therapy, by End Users USD Million (2021-2026)
  • Table 203. Europe HER2 Targeted Therapy, by Treatment USD Million (2021-2026)
  • Table 204. Europe HER2 Targeted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 205. Germany HER2 Targeted Therapy, by Therapy USD Million (2021-2026)
  • Table 206. Germany HER2 Targeted Therapy, by End Users USD Million (2021-2026)
  • Table 207. Germany HER2 Targeted Therapy, by Treatment USD Million (2021-2026)
  • Table 208. Germany HER2 Targeted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 209. France HER2 Targeted Therapy, by Therapy USD Million (2021-2026)
  • Table 210. France HER2 Targeted Therapy, by End Users USD Million (2021-2026)
  • Table 211. France HER2 Targeted Therapy, by Treatment USD Million (2021-2026)
  • Table 212. France HER2 Targeted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 213. Italy HER2 Targeted Therapy, by Therapy USD Million (2021-2026)
  • Table 214. Italy HER2 Targeted Therapy, by End Users USD Million (2021-2026)
  • Table 215. Italy HER2 Targeted Therapy, by Treatment USD Million (2021-2026)
  • Table 216. Italy HER2 Targeted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 217. United Kingdom HER2 Targeted Therapy, by Therapy USD Million (2021-2026)
  • Table 218. United Kingdom HER2 Targeted Therapy, by End Users USD Million (2021-2026)
  • Table 219. United Kingdom HER2 Targeted Therapy, by Treatment USD Million (2021-2026)
  • Table 220. United Kingdom HER2 Targeted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 221. Netherlands HER2 Targeted Therapy, by Therapy USD Million (2021-2026)
  • Table 222. Netherlands HER2 Targeted Therapy, by End Users USD Million (2021-2026)
  • Table 223. Netherlands HER2 Targeted Therapy, by Treatment USD Million (2021-2026)
  • Table 224. Netherlands HER2 Targeted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 225. Rest of Europe HER2 Targeted Therapy, by Therapy USD Million (2021-2026)
  • Table 226. Rest of Europe HER2 Targeted Therapy, by End Users USD Million (2021-2026)
  • Table 227. Rest of Europe HER2 Targeted Therapy, by Treatment USD Million (2021-2026)
  • Table 228. Rest of Europe HER2 Targeted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 229. MEA HER2 Targeted Therapy, by Country USD Million (2021-2026)
  • Table 230. MEA HER2 Targeted Therapy, by Therapy USD Million (2021-2026)
  • Table 231. MEA HER2 Targeted Therapy, by End Users USD Million (2021-2026)
  • Table 232. MEA HER2 Targeted Therapy, by Treatment USD Million (2021-2026)
  • Table 233. MEA HER2 Targeted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 234. Middle East HER2 Targeted Therapy, by Therapy USD Million (2021-2026)
  • Table 235. Middle East HER2 Targeted Therapy, by End Users USD Million (2021-2026)
  • Table 236. Middle East HER2 Targeted Therapy, by Treatment USD Million (2021-2026)
  • Table 237. Middle East HER2 Targeted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 238. Africa HER2 Targeted Therapy, by Therapy USD Million (2021-2026)
  • Table 239. Africa HER2 Targeted Therapy, by End Users USD Million (2021-2026)
  • Table 240. Africa HER2 Targeted Therapy, by Treatment USD Million (2021-2026)
  • Table 241. Africa HER2 Targeted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 242. North America HER2 Targeted Therapy, by Country USD Million (2021-2026)
  • Table 243. North America HER2 Targeted Therapy, by Therapy USD Million (2021-2026)
  • Table 244. North America HER2 Targeted Therapy, by End Users USD Million (2021-2026)
  • Table 245. North America HER2 Targeted Therapy, by Treatment USD Million (2021-2026)
  • Table 246. North America HER2 Targeted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 247. United States HER2 Targeted Therapy, by Therapy USD Million (2021-2026)
  • Table 248. United States HER2 Targeted Therapy, by End Users USD Million (2021-2026)
  • Table 249. United States HER2 Targeted Therapy, by Treatment USD Million (2021-2026)
  • Table 250. United States HER2 Targeted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 251. Canada HER2 Targeted Therapy, by Therapy USD Million (2021-2026)
  • Table 252. Canada HER2 Targeted Therapy, by End Users USD Million (2021-2026)
  • Table 253. Canada HER2 Targeted Therapy, by Treatment USD Million (2021-2026)
  • Table 254. Canada HER2 Targeted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 255. Mexico HER2 Targeted Therapy, by Therapy USD Million (2021-2026)
  • Table 256. Mexico HER2 Targeted Therapy, by End Users USD Million (2021-2026)
  • Table 257. Mexico HER2 Targeted Therapy, by Treatment USD Million (2021-2026)
  • Table 258. Mexico HER2 Targeted Therapy, by Distribution Channel USD Million (2021-2026)
  • Table 259. Research Programs/Design for This Report
  • Table 260. Key Data Information from Secondary Sources
  • Table 261. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global HER2 Targeted Therapy: by Therapy USD Million (2015-2020)
  • Figure 5. Global HER2 Targeted Therapy: by End Users USD Million (2015-2020)
  • Figure 6. Global HER2 Targeted Therapy: by Treatment USD Million (2015-2020)
  • Figure 7. Global HER2 Targeted Therapy: by Distribution Channel USD Million (2015-2020)
  • Figure 8. South America HER2 Targeted Therapy Share (%), by Country
  • Figure 9. Asia Pacific HER2 Targeted Therapy Share (%), by Country
  • Figure 10. Europe HER2 Targeted Therapy Share (%), by Country
  • Figure 11. MEA HER2 Targeted Therapy Share (%), by Country
  • Figure 12. North America HER2 Targeted Therapy Share (%), by Country
  • Figure 13. Global HER2 Targeted Therapy share by Players 2020 (%)
  • Figure 14. Global HER2 Targeted Therapy share by Players (Top 3) 2020(%)
  • Figure 15. Global HER2 Targeted Therapy share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. Roche (Switzerland) Revenue: by Geography 2020
  • Figure 19. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 20. Sanofi (France) Revenue: by Geography 2020
  • Figure 21. Byondis (Netherlands) Revenue, Net Income and Gross profit
  • Figure 22. Byondis (Netherlands) Revenue: by Geography 2020
  • Figure 23. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. Novartis (Switzerland) Revenue: by Geography 2020
  • Figure 25. Astrazeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. Astrazeneca (United Kingdom) Revenue: by Geography 2020
  • Figure 27. Daiichi Sankyo (Japan) Revenue, Net Income and Gross profit
  • Figure 28. Daiichi Sankyo (Japan) Revenue: by Geography 2020
  • Figure 29. Genentech (United States) Revenue, Net Income and Gross profit
  • Figure 30. Genentech (United States) Revenue: by Geography 2020
  • Figure 31. Bristol Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 32. Bristol Myers Squibb (United States) Revenue: by Geography 2020
  • Figure 33. Eisai (Japan) Revenue, Net Income and Gross profit
  • Figure 34. Eisai (Japan) Revenue: by Geography 2020
  • Figure 35. Kyowa Kirin (Japan) Revenue, Net Income and Gross profit
  • Figure 36. Kyowa Kirin (Japan) Revenue: by Geography 2020
  • Figure 37. Global HER2 Targeted Therapy: by Therapy USD Million (2021-2026)
  • Figure 38. Global HER2 Targeted Therapy: by End Users USD Million (2021-2026)
  • Figure 39. Global HER2 Targeted Therapy: by Treatment USD Million (2021-2026)
  • Figure 40. Global HER2 Targeted Therapy: by Distribution Channel USD Million (2021-2026)
  • Figure 41. South America HER2 Targeted Therapy Share (%), by Country
  • Figure 42. Asia Pacific HER2 Targeted Therapy Share (%), by Country
  • Figure 43. Europe HER2 Targeted Therapy Share (%), by Country
  • Figure 44. MEA HER2 Targeted Therapy Share (%), by Country
  • Figure 45. North America HER2 Targeted Therapy Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Roche (Switzerland)
  • Sanofi (France)
  • Byondis (Netherlands)
  • Novartis (Switzerland)
  • Astrazeneca (United Kingdom)
  • Daiichi Sankyo (Japan)
  • Genentech (United States)
  • Bristol Myers Squibb (United States)
  • Eisai (Japan)
  • Kyowa Kirin (Japan)
Additional players considered in the study are as follows:
Life Sciences (Belgium) , OncXerna (United States) , Resilience (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation